Chromosome 1p and 19q Deletions in Glioblastoma Multiforme
Chromosome 1p and 19q Deletions in Glioblastoma Multiforme
复制标题
DOI：
10.1097/pai.0b013e3181a2c6a4
复制
发表时间：
2009-12-01
影响因子：
1.6
通讯作者：
Prayson, Richard A.
中科院分区：
文献类型：
--
作者：
Kaneshiro, David;Kobayashi, Taisei;Prayson, Richard A.
背景：1p 和 19q 染色体缺失已被证明与间变性少突胶质细胞瘤的预后和化疗敏感性相关。在多形性胶质母细胞瘤 (GBM) 中，这些 GBM 改变对预后的影响尚不清楚。 目的：本研究的目的是通过荧光原位杂交鉴定有 1p 或 19q 缺失证据的 GBM 患者，并将这些结果与临床结果和生存率相关联。 设计：使用荧光原位杂交对 2001 年至 2006 年间切除的 337 例 GBM 进行评估，以识别1p 和 19q 染色体缺失。使用 Cox 回归比较这 2 组与 1p 和 19q 完整肿瘤的对照组之间的生存率。结果：17 名 (5.1%) 患者（9 名男性；诊断时平均年龄 = 61 岁，范围：35 至 84 岁）被发现有 1p 缺失； 8 名患者（47.1%）接受化疗，13 名患者接受放射治疗。该组的平均生存期为 10.8 个月（范围：1 至 50 个月）。 18 名 (5.3%) 患者（11 名女性；平均年龄 = 56 岁，范围：25 至 76 岁）有 19q 缺失； 9 名患者 (50%) 接受了化疗，8 名患者接受过放射治疗。该组的平均生存期为 8.4 个月（范围：1 至 17 个月）。选择了 20 名患者（13 名男性；平均年龄 = 60 岁，范围：40 至 80 岁）组成的对照组，其中 8 名患者（40%）接受了化疗，12 名患者已知接受过放射治疗。该组的平均生存期为 16.4 个月（1 至 59 个月）。九个 (3.7%) 肿瘤具有 1p 和 19q 共缺失，在本研究中未进行评估。孤立的 1p 和 19q 缺失与生存没有显着相关。调整性别、年龄和化疗后，19q 缺失组的生存率显着低于其他组（风险比 = 2.8，P = 0.025）。结论：本研究中 GBM 中孤立的 1p 或 19q 缺失的发生率分别为 6.2% 和 5.3%。与间变性少突胶质细胞瘤相比，单独的 1p 和 19q 缺失并未发现可以改善 GBM 患者的生存率；然而，当根据年龄、性别和化疗进行调整后，19q 缺失似乎会对生存产生负面影响。
Context: Deletions on chromosomes 1p and 19q have been shown to correlate with prognosis and chemosensitivity in anaplastic oligodendrogliomas. In glioblastoma multiforme (GBM), the impact on prognosis of these alterations in GBM is unclear.Objective: The purpose of this study was to identify patients with GBM who had evidence of 1p or 19q deletions by flourescence in situ hybridization, and correlate these results with clinical findings and survival.Design: Three hundred thirty-seven GBM resected between 2001 and 2006 were evaluated using flourescence in situ hybridization to identify deletions on chromosomes 1p and 19q. Cox regression was used to compare survival between these 2 groups and a control group of 1p and 19q intact tumors.Result: Seventeen (5.1%) patients (9 males; mean age at diagnosis = 61y, range: 35 to 84y) were found to have 1p deletions; 8 patients (47.1%) received chemotherapy and 13 patients received radiation therapy. The mean survival for this group was 10.8 months (range: 1 to 50 mo). Eighteen (5.3%) patients (11 females; mean = 56 y, range: 25 to 76 y) had 19q deletions; 9 patients (50%) received chemotherapy and 8 patients were known to have had radiation therapy. The mean survival of this group was 8.4 months (range: 1 to 17 mo). A control group of 20 patients (13 males; mean = 60y, range: 40 to 80 y) was selected, 8 patients (40%) of who received chemotherapy and 12 patients were known to have had radiation therapy. The mean survival in this group was found to be 16.4 months (1 to 59 mo). Nine (3.7%) tumors had codeletions of 1p and 19q and were not evaluated in this study. Isolated 1p and 19q deletions did not significantly correlate with survival. Adjusting for sex, age, and chemotherapy, the 19q-deleted group had a significantly lower survival (hazard ratio = 2.8, P = 0.025) than the other groups.Conclusions: The incidence of isolated 1p or 19q deletions among GBM in the current study was 6.2% and 5.3%, respectively. In contrast to anaplastic oligodendrogliomas, 1p and 19q deletions alone were not found to improve survival of patients with GBM; however, when adjusted for age, sex, and chemotherapy, 19q deletions seem to negatively impact survival.